Mitochondrial protein alterations in vascular dementia: evidence from Mendelian randomization, transcriptomics, and a chronic hypoperfusion model - Report - MDSpire
Advertisement
Mitochondrial protein alterations in vascular dementia: evidence from Mendelian randomization, transcriptomics, and a chronic hypoperfusion model
Clinical Report: Alterations in Mitochondrial Proteins Associated with Vascular Dementia
Overview
This study identifies mitochondrial proteins linked to vascular dementia (VaD) using Mendelian randomization and transcriptomic analysis. COX5B was highlighted in the analysis, while other proteins showed inconsistencies across different analytical layers.
Background
Vascular dementia is the second most common form of dementia, resulting from chronic cerebral hypoperfusion and leading to cognitive decline. Mitochondrial dysfunction plays a significant role in VaD pathogenesis, yet specific proteins involved remain largely unidentified.
Data Highlights
No numerical data available.
Key Findings
Mendelian randomization identified four proteins associated with VaD: AIFM1, COX5B, NDUFV2, and NUDT5.
COX5B demonstrated consistent evidence across Mendelian randomization, transcriptomic analysis, and in vivo validation.
NUDT5 showed partial consistency but did not meet transcriptomic alteration thresholds.
AIFM1 and NDUFV2 exhibited contradictions between genetic/transcriptomic data and in vivo protein expression.
Donepezil improved VaD pathology but did not alter the expression of the identified proteins.
Clinical Implications
The identification of COX5B as a consistent driver of mitochondrial impairment in VaD suggests it may serve as a reliable therapeutic target. Understanding the complexities of other proteins like AIFM1 and NDUFV2 is essential for future research and potential interventions.
Conclusion
This study emphasizes the importance of a multi-layered approach in identifying specific mitochondrial proteins associated with VaD, particularly highlighting COX5B.
